The U.S. Food and Drug Administration has pushed back its decision on Sanofi’s diabetes therapy Tzield by more than one month, citing reported adverse events including seizures and a treatment-related death. This follows a broader pause in the Trump administration’s fast-track approval program, during which the FDA also delayed Disc Medicine’s bitopertin and Eli Lilly’s orforglipron. Regulatory experts note that Tzield’s safety profile—highlighted by two reported seizures and one fatal event in phase 3 studies—triggered an extended review window now set to conclude in mid-February. Investors will watch closely, as any further delay could influence Sanofi’s U.S. growth projections for its metabolic franchise this year.

On January 15, 2026, China’s National Medical Products Administration approved Sanofi-licensed Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy and Redemplo (plozasiran) for familial chylomicronemia syndrome. These approvals are based on positive phase 3 data: the SEQUOIA-HCM trial demonstrated a 35% improvement in peak oxygen uptake and a 40% reduction in left ventricular outflow obstruction for Myqorzo, while the PALISADE study showed a median 80% triglyceride reduction with Redemplo. Sanofi expects first‐quarter 2026 launches in Greater China, reinforcing its strategy to capture high-growth cardiometabolic markets and offset slowing demand elsewhere.

Sanofi Chief Executive Paul Hudson warned that U.S. vaccine volumes may dip slightly in 2026 due to persistent misinformation and intensified regulatory scrutiny. He cited early internal forecasts projecting a 3–5% decline in influenza and adult booster uptake this season compared with 2025. Hudson emphasized that while core vaccine revenues could soften in the short term, ongoing investments in mRNA platform development and emerging-market expansions are designed to sustain long-term growth. Investors will monitor whether this guidance prompts adjustments to Sanofi’s full-year revenue forecast at the forthcoming earnings call.